MapLight Therapeutics Q3 EPS $(0.97) Beats $(1.16) Estimate
Benzinga Newsdesk 2 hours ago
NewsEarningsEarnings Beats
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.16) by 16.38 percent. This is a 97.39 percent increase over losses of $(37.18) per
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.16) by 16.38 percent. This is a 97.39 percent increase over losses of $(37.18) per share from the same period last year.
